Key Takeaways
- Record quarter, but margin optics are noisy: Highest-ever quarterly revenue and EBITDA were driven by robust volumes and export demand, but sharply higher raw material costs and a ~₹500 crore trading book for the first half compressed percentage margins.
- Energy segment doubled sequentially: Revenue surged from ~₹1,000 crore to ~₹1,900 crore, largely on pricing pass-through and strong gasoline-naphtha cracks, pulling the portfolio mix toward 30–40% energy in the midterm.
- Zone IV is now live and ramping fast: Phase I commissioned in September 2026, with Calcium Chloride and PEDA plants hitting design capacity within months; a ₹250–350 crore bottom-line target is set for the first 18 months, with EBITDA accretion expected in FY28.
- A 10-year, ₹1,500 crore contract signals the partnership model working: A dedicated manufacturing and supply agreement with a global specialty chemical major, backed by structured capex financing, adds long-term visibility and validates the inbound inquiry trend from Western markets.
- What to watch next quarter: Whether PDA chain traction resumes as guided, the pace of Zone IV capitalization (~₹1,800–1,900 crore of CWIP by March 2027), and any softening in energy cracks during the winter season.
Zone IV: Commissioning, Ramp-Up & Financial Trajectory
- Phase I operational: Calcium Chloride unit, PEDA plant, and a section of the Multipurpose Plant (MPP) were commissioned on September 7, 2026, and are undergoing stabilization, having achieved designed capacity and quality norms in many cases.
- Ramp-up speed exceeded expectations: Calcium Chloride achieved more than design capacity within its first three months of operation; PEDA hit design capacity and design norms within the first two months of its operation, giving management confidence in superior ramp-up for subsequent products.
- Product rollout cadence: 5 to 10 products are planned in FY27, expanding to 20 to 25 products across 5 chemistry blocks by FY28; the remaining 4 chemistry blocks are expected online within this financial year.
- Bottom-line target, not revenue guidance: Management declined to give a peak revenue number, citing that revenue can go "completely haywire" on crude price swings, and instead set a ₹250 crore to ₹350-odd crore bottom-line target from Zone IV for the first 18 months.
- EBITDA accretion timeline: The aspiration is for Zone IV to be additive to EBITDA in FY28 itself, with commissioning completing within FY27 and ramp-up continuing throughout FY28.
- Capitalization trigger: A significant chunk of the current CWIP, approximately ₹1,800–1,900 crore, is expected to be capitalized by March 31, 2027, which will bring associated fixed costs into the P&L around Q4.
- Product mix strategy: The portfolio combines chlorotoluene and downstream value chain products, toluene side-chain chlorination value chain products, and specialty products from specific customer requirements that are fit-for-purpose for the asset, with the objective of maximizing contribution.
Suyog Kotecha: "The good news is that whatever we have commissioned in Zone IV, it has achieved the ramp-up, the scale, both in terms of efficiency norms and the capacity norms in a relatively short span of time. So we have been able to do first time right across many of these capacities."
Energy Portfolio: The Quarter's Swing Factor
- Revenue doubled sequentially: Energy segment revenue moved from ~₹1,000 crore in Q1 to ~₹1,900 crore in Q2, largely led by pricing pass-through of higher raw material costs and some volume growth, while other segments did not show similar sequential growth except Pharma.
- Spreads maintained, not expanded: Despite the inflationary raw material environment, spreads were maintained in Q2, supported by gasoline-naphtha cracks that were very robust at $20-plus per barrel in the last quarter.
- Domestic ramp-up added thrust: Domestic energy sales saw a robust ramp-up driven by Calcium Chloride volume and revenue contribution increasing after Zone IV commissioning with significant price uptick, domestic demand picking up for Fuel Additives, and some exported volume being bought in the domestic market.
- Fuel Additives capacity utilization strong: Utilization remained strong in Q2 following the expansion from 290 KTPA to 360 KTPA completed in Q1 FY26.
- Midterm portfolio share: The energy segment is expected to settle between 30% to 40% of the overall portfolio in the midterm, especially as Zone IV ramps up and revenue from that site balances the portfolio, with pricing corrections in global markets also contributing.
- Near-term priority is stabilization, not expansion: Management's focus is on stabilizing the current 360 KT capacity and strengthening the integrated value chain presence for more robust, stable earnings; further expansion may be evaluated after that.
- Strategic feedstock initiatives in motion: The company is in an exploratory phase for initiatives ranging from strategic partnerships to manufacturing some feedstocks on its own, with implementation expected in the next three to four months.
New Long-Term Contract & Partnership Model
- 10+ year, ₹1,500 crore agreement signed: On October 13, 2026, the company announced a dedicated manufacturing and supply agreement with a global specialty chemical major, with a dedicated facility, structured capex financing under US$25 million, and commercial operations targeted for FY29.
- First-time technology for the company: The technology being worked on is new for Aarti, and the know-how is expected to benefit the company significantly in the long term; management declined to comment on whether the product is manufactured by anyone else in India.
- Contract structure protects margins: Fixed costs are very well covered, including inflationary clauses, and protection of conversion margins is relatively well assured.
- Inbound inquiry flow rising: Management has seen very good traction in inbound inquiries for long-term specialty chemical manufacturing partnerships in India to serve markets in Europe, Japan, and the US, and is in active conversation with some of these customers.
- Partnership share ambition: Long-term partnerships currently represent ~25–30% of the business, and management hopes this share will increase as more such partnerships are concluded.
- New application areas in conversation: Strategic projects backed by customer demand are under active discussion in personal care, flavors and fragrances, batteries, and defense, many backed by long-term contracts for offtake, capital recovery, and margin profile assurance.
Suyog Kotecha: "We have seen very good traction when it comes to inbound inquiries to do long-term partnerships for specialty chemical manufacturing in India to serve markets in Europe, in Japan, in U.S. That inquiry flow has gone up, and we are in active conversation with some of these customers."
Margin Mechanics: The Inflation Pass-Through Story
- Raw material cost surge was broad-based: Escalating Middle East geopolitical tensions triggered significant crude oil volatility, driving raw material cost inflation across key chemical value chains; almost all raw materials saw significant price increases, with Sulphur prices surging over 5-6x and freight costs sharply elevated.
- Pass-through lag compressed spreads in select chains: In Agrochemicals and some other segments, quarterly contracts create a lag of one quarter in pass-through of pricing, causing spreads to compress for a three-to-four-month time frame before price pass-through occurs.
- Acid value chain took a direct hit: Inflationary sulfur prices could not be fully passed on, and margins got compressed quite significantly in the acid value chain.
- Per-kg spread stability in two-thirds of portfolio: In almost two-thirds of the portfolio, spreads have been maintained on a per-kg basis, providing a floor under absolute contribution even as percentage margins optically decline.
- Trading volume amplified the margin drag: Trading volume of ~₹500 crore in H1 was done in anticipation to build the market for expanded capacities and was partially responsible for the lower margin in the quarter.
- Inventory on the waters delays margin recognition: ₹800–1,000 crore of inventory on the waters impacts reported margins because margins accrue to the P&L only on delivery, not on procurement.
- Management redirects the margin conversation: When asked what sustainable margins would have been with full pass-through, management declined to talk about percentage margins, stating it is a factor of top line which can swing significantly, and redirected focus to underlying volume growth, absolute rupees crore in contribution margins and EBITDA, and balance sheet health.
Suyog Kotecha: "Tere is definitely an upside in the NCB chain that we are seeing compared to our assumption."
Chain-by-Chain Performance & Outlook
- NCB chain: Asset utilization remains elevated, and spreads have expanded compared to original assumptions, providing an upside; capacity expansion is under evaluation by management given elevated utilization.
- PDA chain: Huge overcapacity and dumping by Chinese players in the global market created a short-term drag on Q2 performance; the company is trying to protect minimum margin levels while evaluating use of part of the capacity for other products with favorable margins and demand; traction is expected to resume in Q3 FY27, underpinned by accelerating DCB demand.
- Parma & Fluoro Products: Pricing and volume gains in PNCB, with key paracetamol building blocks seeing robust demand bolstered by capacity rationalizations in China; Fluoro products' margins continue to remain under pressure.
- Dyes & Pigments: Q1 softness from reluctance to accept higher inflation-linked pricing reversed in Q2 as the market realized elevated prices are here to stay and some Chinese exports got impacted, reducing product availability from China.
- Polymers & Additives: Demand dynamics across high-end engineering, EV, and defense markets remain robust, though softness in the PDA chain created a short-term drag.
- MMA: Ran almost at full capacity in Q2; the product is still going through its business development phase, with a lot of additional market yet to be discovered; end-market performance and affordability of octane boosters linked to end-market cracks are the more important elements to track.
- China anti-involution as a margin catalyst: If China's current stance linked to anti-involution and VAT rebate removal gets passed on to multiple other value chains beyond NCB, it could create upside in margins; a similar move in the PDA chain would make the turnaround "pretty dramatic."
Suyog Kotecha: "Te biggest lever for there was China's anti-involution strategy, which impacted NCB chain, right, where we removed the VAT subsidy rebates that Chinese players used to get, which was as high as 13% of the product price and if something similar happens like that in PDA chain, of course, the turnaround will be pretty dramatic."
Balance Sheet, Capex & Strategic Priorities
- Fund-raise to deleverage: The board approved an enabling resolution to raise up to ₹1,000 crore, approved by shareholders in an EGM on October 31, 2026; the primary objective is to deleverage the balance sheet, strengthen the financial position, and build long-term flexibility to support strategic growth initiatives beyond FY28–FY29.
- Major capex cycle nearing completion: As the major capex cycle progresses toward completion, the strategic priority is shifting toward maximizing asset utilization, expanding value-added chemistries, and strengthening portfolio resilience through strategic partnerships.
- Brownfield and debottlenecking only: Management is not looking at big capex programs; the focus is on brownfield and debottlenecking with limited incremental capex across Fuel Additives, DCB chains, and NCB debottlenecking, with capital intensity not expected to be significantly higher.
- Inventory risk acknowledged as structural: Given the significantly import- and export-heavy nature of the business, some risk on inventory loss will always remain and cannot be fully eliminated, though the company tries to forward-book product contracts to pass on raw material pricing to customers and minimize exposure.
- Cost and efficiency levers mostly implemented: A dedicated internal team focuses on achieving targets across yield, energy, throughput quality, and fixed cost optimization; the impact has started to become visible in the bottom line and will become increasingly visible going forward.
- Augene Chemicals JV progressing: The facility is ready, trial production is underway, and the order book is gaining traction; commercial production is expected to commence soon.
- Aarti Circularity on track: Project execution remains on track.
Suyog Kotecha: "Watever best we can get in brownfield and debottlenecking versions is what we are trying to get done quickly and accrue to the bottom line."
Guidance & Commitments
| Comitment | Specifics | Timline |
|---|---|---|
| PDA chain traction resumption | Traction to resume, underpinned by accelerating DCB demand | Q3 FY27 |
| Zone IV product rollout | 5 to 10 products in FY27, expanding to 20–25 products across 5 chemistry blocks by FY28; remaining 4 chemistry blocks online within FY27 | FY27–FY28 |
| Zone IV bottom-line contribution | ₹250 crore to ₹350-odd crore in first 18 months; aspiration to be EBITDA additive in FY28 | FY28 |
| Zone IV capitalization | ~₹1,800–1,900 crore of CWIP capitalized | By March 31, 2027 |
| New long-term contract commercial operations | Dedicated facility operational, revenue potential ~₹1,500 crore | FY29 |
| Fund-raise execution | Up to ₹1,000 crore to deleverage balance sheet | Post-EGM approval (Oct 31, 2026) |
| Energy feedstock strategic initiatives | Implementation of initiatives from partnerships to own manufacturing | Next 3–4 months |
| Energy portfolio share | Settle between 30% to 40% of overall portfolio | Midterm |
| Cost and efficiency levers | Impact increasingly visible in bottom line | Going forward |
| FY28 EBITDA trajectory | Three levers (cost efficiency, operating leverage, capex ramp-up) provide line of sight to guided range | FY28 |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue | ₹3,887 cr, up 73% YoY |
| EBITDA | ₹418 cr, up 44% YoY; highest-ever quarterly EBITDA |
| H1 FY27 EBITDA | Over ₹802 cr, up over 58% YoY from ₹507 cr in H1 FY26 |
| PAT | ₹169 cr, up ~60% YoY |
| H1 FY27 PAT | ₹324 cr, up 117% YoY from ₹149 cr in H1 FY26 |
| Net debt | Over ₹4,650 cr |
| FY27 capex plan | ₹700 cr to ₹800 cr |
| FY28 EBITDA target | ₹1,800 cr to ₹2,200 cr |
| Energy segment share of portfolio | 50% of total portfolio in Q2; midterm expectation 30% to 40% |
| Fuel Additives capacity | 360 KTPA, expanded from 290 KTPA in Q1 FY27 |
| DCB capacity | 140 KTPA, post-debottlenecking |
| Zone IV CWIP | ₹1,800 cr to ₹1,900 cr, expected capitalized by March 31, 2027 |
| Zone IV bottom-line target | ₹250 cr to ₹350 cr in first 18 months |
| New long-term contract revenue potential | ~₹1,500 cr, 10+ year agreement; commercial operations targeted for FY29 |
| Working capital days | 55 to 60 days, optimized level |
| Portfolio on pass-through basis | More than 2/3rd |